<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601353</url>
  </required_header>
  <id_info>
    <org_study_id>ED1001</org_study_id>
    <nct_id>NCT01601353</nct_id>
  </id_info>
  <brief_title>Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction</brief_title>
  <official_title>Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tissue Genesis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tissue Genesis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of adipose derived cells for&#xD;
      the treatment of erectile dysfunction symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is being conducted to determine the safety and efficacy of injecting autologous&#xD;
      adipose derived cells into the penis of men with erectile dysfunction. Subjects will be&#xD;
      randomized into a treatment and control arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events that occur during or after the procedure to measure safety and tolerability</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Erectile function</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment assessment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erection hardness</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of adipose derived cells into penis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention through 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Genesis Cell Isolation System</intervention_name>
    <description>Liposuction followed by injection of autologous adipose derived cells</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men aged 40 - 70&#xD;
&#xD;
          2. Willing and able to provide written informed consent&#xD;
&#xD;
          3. Chronic, organic erectile dysfunction (ED), duration at least 0.5 years, with baseline&#xD;
             International Index of Erectile Function - Erectile Function (IIEF-EF) score of &lt; 26&#xD;
&#xD;
          4. Willing to complete questionnaires&#xD;
&#xD;
          5. Involved in a monogamous, heterosexual relationship for at least 3 months with both&#xD;
             partners motivated to have or attempt sexual intercourse at least 4 times per month&#xD;
             beginning two weeks after study treatment (subject reported)&#xD;
&#xD;
          6. Not interested or able to use oral PDE-5 inhibitor (PDE-5i) drug therapy, and willing&#xD;
             to forgo these treatments for the first 6-month period following study treatment (in&#xD;
             addition may include a minimum 4-week washout since last PDE-5i use prior to&#xD;
             completion of the baseline erectile function assessments and study treatment)&#xD;
&#xD;
          7. Willing to limit alcohol intake and eliminate use of recreational drugs for sexual&#xD;
             encounters&#xD;
&#xD;
          8. Willing to undergo a minor surgical procedure and injection&#xD;
&#xD;
          9. Abdominal area amenable to liposuction of at least 60-120 cc of adipose tissue based&#xD;
             on Investigator examination&#xD;
&#xD;
         10. Mentally competent and able to understand all study requirements (based on&#xD;
             investigator assessment)&#xD;
&#xD;
         11. Willing to be available for all baseline, treatment and follow-up examinations&#xD;
             required by protocol&#xD;
&#xD;
         12. Willing to forego participation in any other study throughout the duration of this&#xD;
             study unless receiving prior approval by Sponsor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of prostate cancer which requires additional radiotherapy or other adjuvant&#xD;
             therapy&#xD;
&#xD;
          2. Previous pelvic or abdominal radiation therapy&#xD;
&#xD;
          3. Previous, concomitant or scheduled use of anti-androgen therapy&#xD;
&#xD;
          4. Untreated hypogonadism or low serum total testosterone (&lt; 200 ng/dL)&#xD;
&#xD;
          5. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history&#xD;
             of priapism&#xD;
&#xD;
          6. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin&#xD;
             entry for abdominal liposuction or penile injection (including abdominal trauma and&#xD;
             abdominal skin cancer (basal cell carcinoma, squamous cell carcinoma, and melanoma))&#xD;
&#xD;
          7. Use of any non-study treatment for erectile dysfunction within 4 weeks of study&#xD;
             treatment and a lack of willingness to continue through 6 months after study treatment&#xD;
&#xD;
          8. Any previous penile implant or penile vascular surgery&#xD;
&#xD;
          9. Current or previous malignancy other than localized prostate cancer or nonabdominal,&#xD;
             non-melanoma skin cancer (successfully treated or treatable by curative excision or&#xD;
             other local curative therapy- abdominal skin cancer is exclusionary as indicated in&#xD;
             criteria 6)&#xD;
&#xD;
         10. Uncontrolled hypertension or hypotension (systolic blood pressure &gt; 170 or &lt; 90 mm Hg,&#xD;
             and diastolic blood pressure &gt; 100 or &lt; 50 mm Hg)&#xD;
&#xD;
         11. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction&#xD;
             within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart&#xD;
             failure) or symptomatic postural hypotension within 6 months before screening&#xD;
&#xD;
         12. Hemoglobin A1c &gt; 8% within 8 weeks prior to study treatment&#xD;
&#xD;
         13. Current urinary tract or bladder infection&#xD;
&#xD;
         14. Drug, alcohol, or substance abuse reported within the last three years (subject&#xD;
             reported)&#xD;
&#xD;
         15. Subject's sexual partner is &lt; 18 years of age, nursing, or known to be pregnant at&#xD;
             screening, or wishes to become pregnant during the study period, or has any&#xD;
             gynecologic problems, major medical conditions, or other factors that would limit&#xD;
             participation in sexual intercourse to less than 4 times per month (subject reported)&#xD;
&#xD;
         16. Weight less than 154 lbs/ 70 kg, or BMI â‰¥ 30&#xD;
&#xD;
         17. Unable to limit or avoid nonsteroidal anti-inflammatory drugs(NSAIDs) for 15 days&#xD;
             prior to treatment (subject reported)&#xD;
&#xD;
         18. Bleeding or clotting disorder, use of anticoagulant therapy, or history of easy or&#xD;
             excessive bruising&#xD;
&#xD;
         19. Lab values for Complete Blood Count(CBC), Prothrombin Time(PT)/Partial Thromboplastin&#xD;
             Time(PTT)/International Normalized Ration(INR), liver function and creatinine falling&#xD;
             outside the normal lab values (see section 5.3 for further detail)&#xD;
&#xD;
         20. Systemic autoimmune disorder&#xD;
&#xD;
         21. Significant active systemic or localized infection&#xD;
&#xD;
         22. Receiving immunosuppressant medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Diego Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

